Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $77.00 price target on the biotechnology company’s stock. CAPR has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and set […]
More Stories
Insider Selling: Live Oak Bancshares, Inc. (NASDAQ:LOB) CAO Sells 12,588 Shares of Stock
Live Oak Bancshares, Inc. (NASDAQ:LOB – Get Free Report) CAO John W. Sutherland sold 12,588 shares of the company’s stock...
MoneyLion Inc. (NYSE:ML) CEO Sells $1,612,854.63 in Stock
MoneyLion Inc. (NYSE:ML – Get Free Report) CEO Diwakar Choubey sold 20,133 shares of the firm’s stock in a transaction...
Phong Le Sells 1,252 Shares of MicroStrategy Incorporated (NASDAQ:MSTR) Stock
MicroStrategy Incorporated (NASDAQ:MSTR – Get Free Report) CEO Phong Le sold 1,252 shares of the stock in a transaction dated...
Incitec Pivot Limited (OTCMKTS:INCZY) to Issue Dividend of $0.04
Incitec Pivot Limited (OTCMKTS:INCZY – Get Free Report) announced a dividend on Thursday, November 14th,NASDAQ Dividends reports. Investors of record...
National Bankshares, Inc. (NASDAQ:NKSH) Plans Dividend of $0.78
National Bankshares, Inc. (NASDAQ:NKSH – Get Free Report) announced a dividend on Wednesday, November 13th,NASDAQ Dividends reports. Stockholders of record...
Secom Co., Ltd. (OTCMKTS:SOMLY) Sees Large Increase in Short Interest
Secom Co., Ltd. (OTCMKTS:SOMLY – Get Free Report) saw a large growth in short interest during the month of October....